An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in regulating skeletal muscle size. Several other ligands, including GDF11 and the activins, signal through this pathway, suggesting that the ActRII receptors are major regulatory nodes in the regulation of muscle mass. We have developed a novel, human anti-ActRII antibody (bimagrumab, or BYM338) to prevent binding of ligands to the receptors and thus inhibit downstream signaling. BYM338 enhances differentiation of primary human skeletal myoblasts and counteracts the inhibition of differentiation induced by myostatin or activin A. BYM338 prevents myostatin- or activin A-induced atrophy through inhibition of Smad2/3 phosphorylation, thus sparing the myosin heavy chain from degradation. BYM338 dramatically increases skeletal muscle mass in mice, beyond sole inhibition of myostatin, detected by comparing the antibody with a myostatin inhibitor. A mouse version of the antibody induces enhanced muscle hypertrophy in myostatin mutant mice, further confirming a beneficial effect on muscle growth beyond myostatin inhibition alone through blockade of ActRII ligands. BYM338 protects muscles from glucocorticoid-induced atrophy and weakness via prevention of muscle and tetanic force losses. These data highlight the compelling therapeutic potential of BYM338 for the treatment of skeletal muscle atrophy and weakness in multiple settings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“blocking these receptors can result in profound muscle growth in animals and humans18–22”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [19]
In the citing paper
“Interestingly, STC2 is among the genes that are downregulated in skeletal muscle from mice following bimagrumab (activin type II receptor antagonist) treatment [149].”
From Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting (2023) · cites this paper as [149]
In the citing paper
“Myostatin is secreted by the myocytes and inhibits their differentiation and proliferation.”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
In the citing paper
“Myostatin and Activin receptor type 2 (ActRII) inhibitors have been developed and shown to increase muscle mass and strength and as well as improve insulin sensitivity in vitro (94, 95).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
In the citing paper
“Its level increased in individuals with sarcopenia and/or obesity.”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752 · cited 1×
“This restoration of AKT phosphorylation is important, since AKT has been shown in prior studies to be required for weight-bearing-induced skeletal muscle hypertrophy; we have also previously shown that AKT activates mTOR-mediated phosphorylation of p70S6 kinase in skeletal muscle (49) and inhibits GSK3, resulting in m…”
BackgroundSelf-citationDouble muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039 · cited 1×
“In addition to myostatin (5, 6), other negative regulators of muscle mass have been reported to signal through ActRIIB, including activin A (10–13), while some uncertainty with regard to the contribution of the closely related GDF11 at regulating muscle mass and function remains (13–15).”
BackgroundRegulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 3×
“Prior studies had suggested this as well (10, 18), but this is the first demonstration that an antibody directed at the ActRII receptor can induce significantly greater hypertrophy than myostatin inhibition alone; the point had been made with the ActRIIB trap, but that molecule can actually also bind other ligands tha…”
BackgroundRommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1009 · Cited by 1,583 · cited 1×
“This restoration of AKT phosphorylation is important, since AKT has been shown in prior studies to be required for weight-bearing-induced skeletal muscle hypertrophy; we have also previously shown that AKT activates mTOR-mediated phosphorylation of p70S6 kinase in skeletal muscle (49) and inhibits GSK3, resulting in m…”
BackgroundSelf-citationMyostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Clop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 940 · cited 3×
“Intervention at the ActRIIB pathway level under cancer cachexia conditions in mice showed a clear benefit not only for muscle preservation but also for overall survival, without affecting tumor growth (24).”
BackgroundInduction of Cachexia in Mice by Systemically Administered Myostatin
Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkinson, K. N., McPherron, A. C., Wolfman, N. M., & Lee, S.-J. (2002) · Science · doi:10.1126/science.1069525 · Cited by 907
Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00105.2009 · Cited by 792 · cited 21×
“Myostatin’s inhibition of muscle differentiation and hypertrophy has been reported to occur at least partially through a Smad2/3 phosphorylation-dependent blockade of the AKT-mTOR pathway; treatment of muscle with myostatin or activin results in a decrease in the level of phosphorylated AKT (16, 19), which is required…”
BackgroundMethodResultInfluentialSelf-citationThe E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle
Clarke, B. A., Drujan, D., Willis, M. S., Murphy, L. O., Corpina, R. A., Burova, E., Rakhilin, S. V., Stitt, T. N., Patterson, C., Latres, E., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.009 · Cited by 683
Self-citationCohen, S., Brault, J. J., Gygi, S. P., Glass, D. J., Valenzuela, D. M., Gartner, C., Latres, E., & Goldberg, A. L. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200901052 · Cited by 584
Self-citationRebbapragada, A., Benchabane, H., Wrana, J. L., Celeste, A. J., & Attisano, L. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7230-7242.2003 · Cited by 565 · cited 1×
“Myostatin, GDF11, and activins (A and B) bind to and signal through either the ActRIIA or ActRIIB receptor on the cell membrane, with ActRIIB initially identified to be myostatin’s prime receptor (13, 17, 18).”
BackgroundSmad2 and 3 transcription factors control muscle mass in adulthood
Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R., & Sandri, M. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00104.2009 · Cited by 517 · cited 15×
“Myostatin’s inhibition of muscle differentiation and hypertrophy has been reported to occur at least partially through a Smad2/3 phosphorylation-dependent blockade of the AKT-mTOR pathway; treatment of muscle with myostatin or activin results in a decrease in the level of phosphorylated AKT (16, 19), which is required…”
BackgroundInfluentialInhibition of myostatin in adult mice increases skeletal muscle mass and strength
Whittemore, L.-A., Song, K., Li, X., Aghajanian, J., Davies, M., Girgenrath, S., Hill, J. J., Jalenak, M., Kelley, P., Knight, A., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02953-4 · Cited by 503 · cited 1×
“These include neutralizing antibodies to myostatin (25), a modified myostatin propeptide which blocks myostatin (26), and a soluble ActRIIB-Fc receptor trap (10, 21, 24, 27), all of which increase postnatal muscle growth in mice.”
BackgroundRegulation of muscle growth by multiple ligands signaling through activin type II receptors
Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson, K. N., Wright, J. F., Barker, C., Ehrmantraut, G., Holmstrom, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505996102 · Cited by 501
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
Wagner, K. R., Fleckenstein, J. L., Amato, A. A., Barohn, R. J., Bushby, K., Escolar, D. M., Flanigan, K. M., Pestronk, A., Tawil, R., Wolfe, G. I., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21338 · Cited by 481
Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases
Wolfman, N. M., McPherron, A. C., Pappano, W. N., Davies, M. V., Song, K., Tomkinson, K. N., Wright, J. F., Zhao, L., Sebald, S. M., Greenspan, D. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2534946100 · Cited by 454 · cited 1×
“However, the levels of myostatin reported in humans are lower than those seen in rodents (44–46), and even in rodents, more modest effects are seen when myostatin is blocked in adult animals (33, 47) than when it is blocked during development.”
BackgroundLack of myostatin results in excessive muscle growth but impaired force generation
Amthor, H., Macharia, R., Navarrete, R., Schuelke, M., Brown, S. C., Otto, A., Voit, T., Muntoni, F., Vrbóva, G., Partridge, T., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604893104 · Cited by 425 · cited 1×
“There is some controversy regarding an increase in specific force in myostatin-deficient mice, since the overall increase in mass is so large that while an increase in total force is achieved, the force per mass is actually lower; this could be due to the awkward angling of the fibers in the grossly hypertrophic tissu…”
BackgroundMa, K., Mallidis, C., Bhasin, S., Mahabadi, V., Artaza, J., Gonzalez-Cadavid, N., Arias, J., & Salehian, B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00487.2002 · Cited by 414 · cited 1×
“Administration of high doses of glucocorticoids induces muscle atrophy and is often associated with elevated myostatin levels (38).”
BackgroundBodine, S. C. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.06.011 · Cited by 389 · cited 1×
“Furthermore, muscle atrophy arises after injury because of muscle inactivity resulting from casting, immobilization, or prolonged bed rest (1) and also as a result of the age-related loss of skeletal muscle known as sarcopenia, which is part of the broader syndrome of frailty often observed in elderly individuals (2,…”
BackgroundPI3 Kinase Regulation of Skeletal Muscle Hypertrophy and Atrophy
Glass, D. J. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_78 · Cited by 333 · cited 1×
“Myostatin’s inhibition of muscle differentiation and hypertrophy has been reported to occur at least partially through a Smad2/3 phosphorylation-dependent blockade of the AKT-mTOR pathway; treatment of muscle with myostatin or activin results in a decrease in the level of phosphorylated AKT (16, 19), which is required…”
BackgroundSelf-citationQuadrupling Muscle Mass in Mice by Targeting TGF-ß Signaling Pathways
Lee, S.-J. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000789 · Cited by 316 · cited 1×
“This implication was strengthened by the genetic cross of the myostatin-null mouse with a follistatin transgenic animal, resulting in much greater hypertrophy (48).”
BackgroundMyostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314 · cited 2×
“Phosphorylated Smad2/3 are then translocated to the nucleus and modulate the transcription of target genes, including MyoD (4, 16).”
BackgroundMyostatin Gene Deletion Prevents Glucocorticoid-Induced Muscle Atrophy
Gilson, H., Schakman, O., Combaret, L., Lause, P., Grobet, L., Attaix, D., Ketelslegers, J. M., & Thissen, J. P. (2007) · Endocrinology · doi:10.1210/en.2006-0539 · Cited by 278 · cited 1×
“The myostatin promoter bears several glucocorticoid response elements, and myostatin deletion has been reported to prevent glucocorticoid-induced muscle wasting (39).”
BackgroundRegulation of Muscle Mass by Follistatin and Activins
Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K., Cohn, R. D., & Barton, E. R. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0127 · Cited by 273
Ibebunjo, C., Chick, J. M., Kendall, T., Eash, J. K., Li, C., Zhang, Y., Vickers, C., Wu, Z., Clarke, B. A., Shi, J., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01036-12 · Cited by 267
Self-citationMyostatin propeptide‐mediated amelioration of dystrophic pathophysiology
Bogdanovich, S., Perkins, K. J., Krag, T. O. B., Whittemore, L.-A., & Khurana, T. S. (2005) · The FASEB Journal · doi:10.1096/fj.04-2796com · Cited by 242 · cited 1×
“These include neutralizing antibodies to myostatin (25), a modified myostatin propeptide which blocks myostatin (26), and a soluble ActRIIB-Fc receptor trap (10, 21, 24, 27), all of which increase postnatal muscle growth in mice.”
BackgroundMorley, J. E. (2012) · Family Practice · doi:10.1093/fampra/cmr063 · Cited by 218 · cited 2×
“Furthermore, the loss of skeletal muscle mass associated with old age, called “sarcopenia,” is well documented, and the resulting frailty is a major cause of morbidity and mortality in the rapidly increasing aged population (2).”
BackgroundPost burn muscle wasting and the effects of treatments
Pereira, C., Murphy, K., Jeschke, M., & Herndon, D. N. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.05.009 · Cited by 202 · cited 1×
“Many cachectic settings are accompanied by high cortisol levels, including COPD, kidney cachexia, and acute severe burns (36, 37, 51).”
BackgroundAnker, S. D., Clark, A. L., Kemp, M., Salsbury, C., Teixeira, M. M., Hellewell, P. G., & Coats, A. J. S. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00262-3 · Cited by 190 · cited 2×
“Catabolic conditions are often associated with hypercortisolism, which in turn plays a major role in skeletal muscle atrophy (36, 37).”
BackgroundThe central role of myostatin in skeletal muscle and whole body homeostasis
Elliott, B., Renshaw, D., Getting, S., & Mackenzie, R. (2012) · Acta Physiologica · doi:10.1111/j.1748-1716.2012.02423.x · Cited by 183 · cited 1×
“Finally, there have been suggestions that ActRIIB inhibition can also be helpful in settings of heart failure (43) and in those settings where inflammatory cytokines induce muscle loss; under such conditions, there is an interesting cross talk between the cytokine pathway and TGF- signaling, since downstream of NF- B…”
BackgroundA single ascending‐dose study of muscle regulator ace‐031 in healthy volunteers
Attie, K. M., Borgstein, N. G., Yang, Y., Condon, C. H., Wilson, D. M., Pearsall, A. E., Kumar, R., Willins, D. A., Seehra, J. S., & Sherman, M. L. (2013) · Muscle & Nerve · doi:10.1002/mus.23539 · Cited by 176
Redundancy of myostatin and growth/differentiation factor 11 function
McPherron, A. C., Huynh, T. V., & Lee, S.-J. (2009) · BMC Developmental Biology · doi:10.1186/1471-213x-9-24 · Cited by 165
Wilkes, J. J., Lloyd, D. J., & Gekakis, N. (2009) · Diabetes · doi:10.2337/db08-0245 · Cited by 156 · cited 1×
“, mice with a myostatin loss-of-function mutation (35).”
BackgroundPolge, C., Heng, A., Jarzaguet, M., Ventadour, S., Claustre, A., Combaret, L., Béchet, D., Matondo, M., Uttenweiler‐Joseph, S., Monsarrat, B., et al. (2011) · The FASEB Journal · doi:10.1096/fj.11-180968 · Cited by 146
Souza, T. A., Chen, X., Guo, Y., Sava, P., Zhang, J., Hill, J. J., Yaworsky, P. J., & Qiu, Y. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0290 · Cited by 142 · cited 3×
“The demonstration of preclinical efficacy with a blocking antibody to ActRII establishes a middle ground between the restricted blockade of myostatin, on the one hand, and the use of an ActRIIB soluble receptor as a trap, on the other hand, which can be a sink for ligands such as BMP9/10, binding additional receptors…”
BackgroundBusquets, S., Toledo, M., Orpí, M., Massa, D., Porta, M., Capdevila, E., Padilla, N., Frailis, V., López-Soriano, F. J., Han, H. Q., et al. (2012) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0049-z · Cited by 141 · cited 1×
“Similarly, protection from cancer cachexia using pharmacological intervention with soluble ActRIIB-Fc has been demonstrated through preservation of both muscle mass and function (54).”
BackgroundThe effects of a soluble activin type IIB receptor on obesity and insulin sensitivity
Akpan, I., Goncalves, M. D., Dhir, R., Yin, X., Pistilli, E. E., Bogdanovich, S., Khurana, T. S., Ucran, J., Lachey, J., & Ahima, R. S. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.162 · Cited by 140 · cited 1×
“Furthermore, on the basis of recent findings, blockade of activin type II receptors via an antibody approach may also represent a novel therapeutic modality to aid in switching the metabolic balance between adiposity and muscularity, since an increase in skeletal muscle mass via inhibition of the myostatin pathway was…”
BackgroundFournier, B., Murray, B., Gutzwiller, S., Marcaletti, S., Marcellin, D., Bergling, S., Brachat, S., Persohn, E., Pierrel, E., Bombard, F., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06575-11 · Cited by 135 · cited 1×
“One recently identified mechanism helping to explain this effect is that an ActRIIB antibody has been shown to induce a functional increase in brown fat (56), resulting in enhanced heat production by actually increasing the lipid content in the brown fat tissue (56).”
BackgroundSelf-citationGuide for the Care and Use of Laboratory Animals
National Research Council (1996) · National Academies Press eBooks · doi:10.17226/5140 · Cited by 129
Recent advances in the biology and therapy of muscle wasting
Glass, D., & Roubenoff, R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05809.x · Cited by 128 · cited 1×
“Furthermore, muscle atrophy arises after injury because of muscle inactivity resulting from casting, immobilization, or prolonged bed rest (1) and also as a result of the age-related loss of skeletal muscle known as sarcopenia, which is part of the broader syndrome of frailty often observed in elderly individuals (2,…”
BackgroundSelf-citationLakshman, K. M., Bhasin, S., Corcoran, C., Collins‐Racie, L. A., Tchistiakova, L., Forlow, S. B., Ledger, K. S., Burczynski, M. E., Dorner, A. J., & LaVallie, E. R. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.12.019 · Cited by 120
Fitts, R. H., Romatowski, J. G., Peters, J. R., Paddon-Jones, D., Wolfe, R. R., & Ferrando, A. A. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00573.2006 · Cited by 113 · cited 2×
“Catabolic conditions are often associated with hypercortisolism, which in turn plays a major role in skeletal muscle atrophy (36, 37).”
BackgroundMuscle growth after postdevelopmental myostatin gene knockout
Welle, S., Bhatt, K., Pinkert, C. A., Tawil, R., & Thornton, C. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00531.2006 · Cited by 113 · cited 1×
“However, the levels of myostatin reported in humans are lower than those seen in rodents (44–46), and even in rodents, more modest effects are seen when myostatin is blocked in adult animals (33, 47) than when it is blocked during development.”
BackgroundTerpos, E., Kastritis, E., Christoulas, D., Gkotzamanidou, M. A., Eleutherakis‐Papaiakovou, E., Kanellias, N., Παπαθεοδώρου, Α., & Dimopoulos, M. A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds068 · Cited by 109 · cited 1×
“Many human cancers present with altered expression of activin A, associated with a more malignant phenotype (22, 23), and tumors can also induce the release of activin A from muscle (12).”
BackgroundTAK-1/p38/nNFκB signaling inhibits myoblast differentiation by increasing levels of Activin A
Trendelenburg, A., Meyer, A., Jacobi, C., Feige, J. N., & Glass, D. J. (2012) · Skeletal Muscle · doi:10.1186/2044-5040-2-3 · Cited by 104 · cited 3×
“In particular, activin A has been found to be upregulated in skeletal muscle after activation of the tumor necrosis factor alpha/TAK-1 signaling pathway (12).”
BackgroundMethodSelf-citationGdf11 Is a Negative Regulator of Chondrogenesis and Myogenesis in the Developing Chick Limb
Gamer, L. W., Cox, K. A., Small, C., & Rosen, V. (2001) · Developmental Biology · doi:10.1006/dbio.2000.9981 · Cited by 92
Lukjanenko, L., Brachat, S., Pierrel, E., Lach-Trifilieff, E., & Feige, J. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071084 · Cited by 82 · cited 1×
“All microarray statistical data analyses were performed as reported previously (31).”
MethodSelf-citationPhysiological and metabolic response to isolated closed-head injury
Deutschman, C. S., Konstantinides, F. N., Raup, S., Thienprasit, P., & Cerra, F. B. (1986) · Journal of neurosurgery · doi:10.3171/jns.1986.64.1.0089 · Cited by 80
Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition
Goncalves, M. D., Pistilli, E. E., Balduzzi, A., Birnbaum, M. J., Lachey, J., Khurana, T. S., & Ahima, R. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012707 · Cited by 69 · cited 4×
“These include neutralizing antibodies to myostatin (25), a modified myostatin propeptide which blocks myostatin (26), and a soluble ActRIIB-Fc receptor trap (10, 21, 24, 27), all of which increase postnatal muscle growth in mice.”
BackgroundInfluentialLi, Z., Zhao, B., Kim, Y., Hu, C. Y., & Yang, J. (2009) · Molecular Reproduction and Development · doi:10.1002/mrd.21111 · Cited by 38
Physiological and metabolic response to isolated closed-head injury
Deutschman, C. S., Konstantinides, F. N., Raup, S., & Cerra, F. B. (1987) · Journal of neurosurgery · doi:10.3171/jns.1987.66.3.0388 · Cited by 34
Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells
Hoda, M. A., Münzker, J., Ghanim, B., Schelch, K., Klikovits, T., László, V., Sahin, E., Bedeir, A., Lackner, A., Döme, B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.519 · Cited by 31 · cited 1×
“Many human cancers present with altered expression of activin A, associated with a more malignant phenotype (22, 23), and tumors can also induce the release of activin A from muscle (12).”
BackgroundGrohmann, M. J., Foulstone, E. J., Welsh, G. I., Holly, J. M. P., Hamilton-Shield, J. P., Crowne, E. C., & Stewart, C. E. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.093906 · Cited by 29 · cited 1×
“Typically, CK activity has been reported to increase throughout differentiation (32).”
BackgroundCharacterization of high-affinity antibodies by electrochemiluminescence-based equilibrium titration
Hänel, C., Satzger, M., Ducata, D. D., Ostendorp, R., & Brocks, B. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.032 · Cited by 29 · cited 1×
“(28); however, a plate-based assay setup was used for detection.”
MethodDagher, A. (2011) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195393484.003.0100 · Cited by 17
Research works printed but not linked: 1
- Glass D, 2010, Curr. Top. Microbiol. Immunol., 346, 267
Cited by
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
GDF11 increases with age and inhibits skeletal muscle regeneration
Egerman, M. A., Cadena, S. M., Gilbert, J. A., Meyer, A., Nelson, H. N., Swalley, S. E., Mallozzi, C., Jacobi, C., Jennings, L. L., Clay, I., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.010 · Cited by 527
“Even though we demonstrated similar direct signaling of GDF11 and myostatin and that this correlated to inhibitory effects by both molecules on the differentiation of human skeletal myoblasts, it was still formally possible that GDF11 might have some unique activity on muscle, distinct from its activation of ActRII/AL…”
InfluentialSelf-citationMechanisms of metabolic dysfunction in cancer-associated cachexia
Petruzzelli, M., & Wagner, E. F. (2016) · Genes & Development · doi:10.1101/gad.276733.115 · Cited by 340
“Furthermore, inhibition of ActRIIB by a humanized monoclonal antibody has been shown to increase skeletal muscle mass and prevent glucocorticoid-induced atrophy in mice (Lach-Trifilieff et al. 2014).”
Heymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338
Cancer cachexia: molecular mechanisms and treatment strategies
Setiawan, T., Sari, I. N., Wijaya, Y. T., Julianto, N. M., Muhammad, J. A., Lee, H., Chae, J. H., & Kwon, H. Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01454-0 · Cited by 315
“The clinical trial of another inhibitor, such as BYM338, which specifically inhibits myostatin and activin A, has been tested in a phase II clinical trial (NCT01925209, 2013), and GDF11 is now being considered in clinical trials [263, 270].”
Background
Metadata
- Authors
- Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., Hatakeyama, S., & Glass, D. J.
- Affiliations
- MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, Basel, Switzerland
- Novartis (Switzerland) (CH)
- Development and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA
- Novartis Institutes for BioMedical Research (CH)
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2014-02-01
- Volume
- 34
- Issue
- 4
- Pages
- 606-618
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC3911487
- OpenAlex
- W2102107385
- Semantic Scholar
- 9ec58206f235e018d6953a27e975ae19a1c51271
- Cited by
- 306
- References
- 58
- Citations by year
- 2026: 22 · 2025: 16 · 2024: 19 · 2023: 21 · 2022: 20 · 2021: 37 · 2020: 29 · 2019: 28 · 2018: 25 · 2017: 18 · 2016: 29 · 2015: 21 · 2014: 19
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis
- MorphoSys
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- activin type II receptor, bimagrumab, myostatin, skeletal muscle hypertrophy, muscle atrophy, Smad2/3 phosphorylation, skeletal myoblast differentiation, activin A, GDF11, muscle weakness, myosin heavy chain degradation, muscle mass regulation
- MeSH terms
- Animals, Antibodies, Monoclonal, Atrophy, Cell Differentiation, Humans, Hypertrophy, Signal Transduction, Muscle, Skeletal, Antibodies, Blocking, Activins, Activin Receptors, Type II, Myoblasts, Skeletal, Mice, Smad2 Protein, Smad3 Protein, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.